MedTrace Logo

Efficacy and Safety of Rivaroxiban Compare With Vitamin K Antagonist Warfarin

NCT03673605 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2018-09-17

No results posted yet for this study

Summary

Title: Efficacy and safety of rivaroxiban compare with vitamin K antagonist warfarin in patients with atrial fibrillation and mitral stenosis among Pakistani population.

Conditions

Interventions

DRUG

Rivaroxaban 15 mg

Rivaroxiban in stroke prevention in patients with Mitral Stenosis and AF.

DRUG

Warfarin

Warfarin in stroke prevention in patients with Mitral Stenosis and AF.

Sponsors & Collaborators

  • PharmEvo Pvt Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-30
Primary Completion
2017-10-30
Completion
2017-12-30

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03673605 on ClinicalTrials.gov